One Important Step to Improving Treatment for Therapy-Resistant Cancers

Cancer Therapies at the Molecular Level in Intracellular Proteins
Cancer Therapies at the Molecular Level in Experimental Antibodies

The use of immunotherapy for cancer has helped many patients with cancers that are difficult to treat or cancers that have spread. However, there have been certain limits on how this treatment works. In some cases, tumors have become resistant to this form of treatment. Researchers have been working on a combination therapeutic approach that shows more promise in effectively fighting cancer.

Experimental Antibody

Researchers at Stanford and Yale developed an experimental antibody that is able to target more immune cells that are involved with the growth of tumors. Current immunotherapy approaches focus on a smaller number of these immune cells, which limits their ability to eliminate cancerous tumors. While these approaches have stopped cancer from spreading in some cases, they have been unable to successfully deal with tumor growth in other cases.

The experimental antibody is able to prevent another type of immune cell, known as a myeloid cell, from contributing to tumor growth and immunotherapy drug resistance.

Combination Immunotherapy

The use of this experimental antibody along with immunotherapy drugs is showing the potential for effectively fighting cancer. Researchers have used it on cell culture models and mouse models that contain human cell membrane proteins. This combination immunotherapy approach limits the growth of tumor cells, making it harder for them to thrive and spread. Researchers still need to do more studies on this experimental antibody in order to determine if it can be used to treat cancer cases that are metastatic or more advanced.

To learn more about immunotherapy for cancer, please visit IsselsĀ®. We offer advanced programs for those who are looking for nontoxic forms of cancer treatment.